Neovasc — Investor Presentation (January 2015)
22 slides from Neovasc's investor presentation, January 2015
Slide 1: Neovasc Inc. Equity Offering
Neovasc Inc. Equity Offering Alexei Marko, CEO Chris Clark, CFO January 2015
Slide 2: Forward-looking statements
Forward-looking statements Statements contained herein that are not based on historical or current fact, including without limitation statements containing the words “anticipates,” “believes,” “may,” “continues,” “estimates,” “expects,” and “will” and words of similar import, constitute “forward- lo
Slide 3: Cardiovascular products for refractory angina and mitral valve disease
Cardiovascular products for refractory angina and mitral valve disease Commercial products and established revenues 3
Slide 4: Management and Board
Management and Board Management ALEXEI MARKO CHRIS CLARK BRIAN MCPHERSON CHIEF EXECUTIVE OFFICER, DIRECTOR CHIEF FINANCIAL OFFICER CHIEF OPERATING OFFICER Almost 20 years experience in Almost 20 years finance and More than 20 years experience in medical device field; Neovasc accounting experience me
Slide 5: 3 product lines targeting significant markets
3 product lines Targeting 3 significant markets Tiara™ Reducer™ Biological Tissue Transcatheter mitral Transcatheter device for Proprietary biological valve replacement refractory angina tissue products for (investigational) (CE marked) implantable medical devices (commercial) 5
Slide 6: Tiara Transcatheter Mitral Valve
Tiara™ Transcatheter Mitral Valve
Slide 7: Minimally invasive device under development for mitral regurgitation
Minimally invasive device under development for millions of patients who experience mitral regurgitation as a result of mitral heart valve disease 7
Slide 8: Mitral Valve Regurgitation (MR)
Mitral Valve Regurgitation (MR) A serious and poorly served condition that requires development of highly specialized devices to address the complex mitral anatomy M I T R AL R E G U RG I TAT I O N VALVE D OES N OT FU LLY C LOS E Results in: • heart failure • death 8
Slide 9: Tiara Addressable market opportunity
Tiara Addressable market opportunity • Estimated that in 2015, ~5.9 million people will suffer from MR in the US and EU • ~40% of these MR patients in US suffer from significant MR • A significant percentage of patients with severe MR are not good candidates for conventional surgical treatment EuroI
Slide 10: Tiara: novel investigational transcatheter mitral valve replacement
Tiara A novel investigational transcatheter Mitral Valve replacement REPLACES THE DISEASED VALVE • Design is specific to mitral anatomy • Does not obstruct left ventricular outflow tract (LVOT) • Quick and repeatable implantation procedure • No need for cardiac bypass 10
Slide 11: Tiara: first human implant January 2014
Tiara January 2014 - first human implant of Tiara Conducted by physicians at St. Paul’s Hospital, Vancouver, Canada Five patients treated to date (four pursuant to compassionate use exemptions, one clinical study subject) EXCELLENT RESULTS FROM FIRST CASES • No procedural complications • Complete re
Slide 12: TIARA-I early feasibility study
TIARA- I Multinational, multicenter early feasibility study in the US, Canada, EU • Observational study of high-risk (operable) patients • Co-Chairs of Study Committee: • Dr. Martin Leon • Dr. Anson Cheung • Enroll up to 30 patients • Participating centers include: Columbia University Medical Center
Slide 13: Reducer Refractory Angina Therapy
Reducer™ Refractory Angina Therapy
Slide 14: Refractory Angina
Refractory Angina Debilitating condition with limited treatment options ~645,000 (estimated) refractory angina patients in the US who are potential candidates substantially larger population of “recurrent” angina patients C AU S E D BY I N AD E Q UAT E B LO O D F LOW TO AR E AS O F T HE HEART M US C
Slide 15: Reducer 20 minute catheter-based procedure
Reducer 20 minute catheter-based procedure • Implanted in the coronary sinus (large vein in heart) • Hourglass shape modulates flow of blood in the heart to elevate CS pressure • Re-distributing blood and increasing flow to ischemic areas in the endocardium • CE marked Reducer modulates flow to elev
Slide 16: COSIRA study primary endpoint achieved
Reducer COSIRA study primary endpoint achieved Double-blind, randomized, sham-controlled, multicenter prospective trial • n = 104 patients at 11 clinical investigation sites • Improvement of ≥2 angina CCS classes (primary endpoint) occurred approximately 2.3x more frequently in Reducer group (P =0.0
Slide 17: Reducer expected next steps
Reducer Expected next steps • Expand enrollment in European Registries • File IDE application and initiate US IDE Study required for FDA approval • Introduce product into pilot centers in Europe • Explore full commercial launch in EU 17
Slide 18: Our Biological Tissue Business
Our Biological Tissue Business Working with industry customers to improve patient care
Slide 19: Biological Tissue
Biological Tissue Proprietary process with 25+ year implant history • Implantable tissue from animal pericardium • Retains mechanical characteristics of natural tissue • Used in implantable medical devices including transcatheter heart valves • Represents 100% of Neovasc’s current revenues 19
Slide 20: Corporate Overview
Corporate Overview • Current cash and cash equivalents / investments position, as of September 30, 2014 of ~$21.7m (low long-term debt) • Listed on TSX and NASDAQ 20
Slide 21: Objectives
Objectives • Tiara Program – Complete TIARA-I enrollment in 2015 – Activities to support CE mark application – Activities to support US IDE application • Reducer Program – Initiate US FDA trial in 2015 – Preparing for EU product launch • Tissue Business – Continue to support infrastructure and devel
Slide 22: Thank you
Thank you Alexei Marko, CEO Chris Clark, CFO January 2015